Should we reduce routine surveillance imaging in pediatric germ cell tumors?
germ cell tumors
radiological exposure
serum tumor markers
surveillance
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
14
12
2022
received:
23
06
2022
accepted:
19
12
2022
pubmed:
11
1
2023
medline:
27
1
2023
entrez:
10
1
2023
Statut:
ppublish
Résumé
This paper retrospectively investigated the site and the detection method of relapses in children and adolescents with malignant germ cell tumors enrolled in the TCGM-AIEOP-2004 Study and subsequently developed a relapse, in order to evaluate a possible reduction in radiological exposure during follow-up. Including all malignant cases, serum tumor markers identified a relapse in more than 70% and, according to the selection criteria published by Children Oncology Group in 2018, in more than 90% of cases. These results confirm the importance of serum tumor markers as a relapse detection method, with possible reduction of radiology exams in specific subgroups.
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30200Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Olson TA, Murray MJ, Rodriguez-Galindo C, et al. Pediatric and adolescent extracranial germ cell tumors: the road to collaboration. J Clin Oncol. 2015;33:3018-3028.
Pearce MS, Salotti JA, Little MP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet. 2012;380:499-505. http://doi.org/10.1016/S0140-6736(12)60815-0
Jezierska M, Gawrychowska A, Stefanowicz J. Diagnostic, prognostic and predictive markers in pediatric germ cell tumors - past, present and future. Diagnostics. 2022;12:278.
Fonseca A, Xia C, Lorenzo AJ, et al. Detection of relapse by tumor markers versus imaging in children and adolescents with nongerminomatous malignant germ cell tumors: a report from the Children's Oncology Group. J Clin Oncol. 2018;37:396-402.
Terenziani M, Bisogno G, Boldrini R, et al. Malignant ovarian germ cell tumors in pediatric patients: the AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) study. Pediatr Blood Cancer. 2017;64:e26568.
Terenziani M, De Pasquale MD, Bisogno G, et al. Malignant testicular germ cell tumors in children and adolescents: the AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) protocol. Urol Oncol Semin Orig Investig. 2018.36:502.e7-502.e13.
D'Angelo P, De Pasquale MD, Barretta F, et al. Malignant sacrococcygeal germ cell tumors in childhood: the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience. Pediatr Blood Cancer. 2021;68:e28812.
Mead GM. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997;15:594-603.
Chakiryan NH, Dahmen A, Cucchiara V, et al. Reliability of serum tumor marker measurement to diagnose recurrence in patients with clinical stage I nonseminomatous germ cell tumors undergoing active surveillance: a systematic review. J Urol. 2021;205:1569-1576.
Miglioretti DL, Johnson E, Williams A, et al. Pediatric computed tomography and associated radiation exposure and estimated cancer risk. JAMA Pediatr. 2017;167:6-14.
Brok J, Lopez-Yurda M, Tinteren HV, et al. Relapse of Wilms’ tumour and detection methods: a retrospective analysis of the 2001 Renal Tumour Study Group-International Society of Paediatric Oncology Wilms’ tumour protocol database. Lancet Oncol. 2018;19:1072-1081.
Morgan MA, Garratt JM, Vaughn DJ. What radiologists should know about microRNA (miRNA) serum biomarkers for germ cell tumors. Abdom Radiol. 2021;46:745-748. https://doi.org/10.1007/s00261-020-02703-3